Lanreotid Sun

Lanreotide, the active ingredient in Lanreotid Sun, is a Somatostatin analog presented as a subcutaneous injection for subcutaneous use. It treats acromegaly and neuroendocrine tumors in adult patients by reducing excess hormone secretion. GNH USA supplies Lanreotid Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lanreotide acts on somatostatin receptors to control hormone‑driven disorders. Acromegaly: reduces excess growth hormone secretion and normalises IGF‑1 levels. Neuroendocrine tumors: inhibits tumor‑related hormone release and slows disease progression. Carcinoid syndrome: alleviates flushing and diarrhoea by suppressing serotonin and other vasoactive substances.

Common Side Effects: - Injection site pain or erythema - Gastro‑intestinal disturbances such as nausea, diarrhoea or abdominal pain - Gallbladder sludge or gallstones - Mild hyperglycaemia or altered glucose tolerance

Serious or Rare Side Effects: - Pancreatitis - Severe hypersensitivity reactions including anaphylaxis - Cardiac arrhythmias in patients with pre‑existing conduction disorders - Acute cholecystitis - Severe hyperglycaemia requiring medical intervention

Lanreotide should be used under specialist supervision with regular monitoring of hormone levels and imaging. Pregnancy: safety not established; avoid unless benefits outweigh risks. Breastfeeding: unknown safety; consider discontinuation. Renal impairment: dose adjustment may be required. Diabetes: monitor blood glucose closely as lanreotide can affect glycaemic control. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide may interact with other agents that affect hormone pathways. Major Interactions (Avoid): - Concomitant use with other somatostatin analogues (e.g., octreotide) – additive hormonal suppression. - High‑dose glucocorticoids – may blunt lanreotide efficacy. Moderate Interactions (Monitor Closely): - Antidiabetic medications – lanreotide can mask hypoglycaemia symptoms. - Oral glucose tolerance tests – results may be altered. - Thyroid hormone replacement – monitor thyroid function tests. - GI motility agents – may exacerbate gastrointestinal side effects.